Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00413751 · ClinicalTrials.gov registry record
Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes
A clinical trial, sponsored by Walter Reed Army Medical Center.
- Completed
- Registry status
- 20
- Enrollment target
NCT00413751 is a clinical trial that has completed, run by Walter Reed Army Medical Center. The registered enrollment target is 20 participants.
The verdict
NCT00413751 has completed, sponsored by Walter Reed Army Medical Center.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.
Interventions
- DRUG Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00413751
The ClinicalTrials.gov registry entry for NCT00413751 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Walter Reed Army Medical Center, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) is the first listed.
NCT00413751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00413751 about?
NCT00413751 is a clinical study titled "Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes". The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.
What is the current status of trial NCT00413751?
This trial is currently completed. The enrollment target is 20 participants.
What interventions are being tested in trial NCT00413751?
The interventions under investigation include: Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) (DRUG).
Who is sponsoring clinical trial NCT00413751?
This trial is sponsored by Walter Reed Army Medical Center, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.